Skip to main content
Premium Trial:

Request an Annual Quote

MRIGlobal, Evogen Enter MDx Product Development Pact

NEW YORK (GenomeWeb News) – MRIGlobal and Evogen today announced a five-year agreement to develop molecular diagnostic products targeting the in vitro and clinical molecular diagnostic markets.

Under the terms of the non-exclusive deal, MRIGlobal is providing product development services to Evogen, which was spun out of MRIGlobal in 2002. Services being provided include assay development, technology transfer, analytical and clinical studies, and commercialization support.

Financial terms of the agreement were not disclosed.

Evogen develops PCR-based molecular diagnostic systems and is based in Lenexa, Kan.

MRIGlobal, previously called Midwest Research Institute, is a not-for-profit research institute and development organization. Its Diagnostics Division provides assay development for menu expansion in in vitro and molecular diagnostics, validation and clinical testing, and other services. It is headquartered in Kansas City, Mo.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.